Schizophrenia drug developer eyes late-stage clinical trial data this month

After the Great Recession, Covid-19 and the war in Ukraine, the Cupertino company's late-stage clinical trial is expected to deliver data this month.

Previous Wells Fargo CEO raises prospect of more layoffs, branch closings and other cost cuts
Next Aronora raises funding round to support clot-buster drug development